Navigation Links
Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
Date:2/20/2009

the drug; (2) that patients in the Study taking R788 experienced increased liver enzymes compared to those patients taking the placebo; (3) that patients in Mexico had higher response rates in both the placebo and treated arms than U.S. patients, which may have disproportionately contributed to the overall reported benefit observed at the higher doses; (4) that the Company lacked adequate internal controls; (5) that, as a result of the foregoing, the Company's statements about its financial well-being and future business prospects were lacking in any reasonable basis when made; and (6) that the Company's Registration Statement was false and misleading at all relevant times.

On December 13, 2007, the Company issued a press release which publicized positive results of a clinical trial of R788. The December 13, 2007 press release was also appended to the Company's Form 8-K filed with the United States Securities and Exchange Commission filed that same day. In response to the positive news of the results of the Study, the price of Rigel's stock increased $17.95 per share to close at $25.95 per share on December 13, 2007, a 224% increase from the previous day's closing price of $8.00 per share.

Subsequently, on or about January 31, 2008, the Company completed its Secondary Public Offering ("SPO"). In connection with its SPO, the Company filed a Registration Statement and Prospectus (collectively referred to as the "Registration Statement") with the SEC. The Registration Statement incorporated by reference the Company's December 13, 2007 press release detailing the results of the Study. The SPO was a financial success for the Company, as it sold more than 5 million shares of stock to investors at a price of $27 per share, for gross proceeds of $135 million.

Thereafter, defendants continued to tout the positive results of the Phase II clinical trial of R788. However, on October 27, 2008 the Company shocked investor
'/>"/>

SOURCE Barroway Topaz Kessler Meltzer & Check, LLP
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
3. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
4. Immtech Announces Posting of Annual Shareholders Meeting Presentation
5. CEL-SCI Corporation Releases Letter to Shareholders
6. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
7. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
8. Roskamp Institute Identifies New Class of Drugs to Treat Alzheimers Disease
9. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
10. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
11. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... LigoCyte Pharmaceuticals, Inc. , a private, clinical-stage ... vaccine products, announced today that it has initiated ... (IM) norovirus vaccine candidate, marking the fourth human ... (VLP) vaccine program.  The Phase I dose-escalation study ...
... Top researchers at the Gastrointestinal Cancer Research Lab at ... clinical applications of BCM-95®, a new patented extract of ... Previous studies have shown that BCM-95 curcumin was 7-10 ... had a retention time in the bloodstream between 8 ...
Cached Medicine Technology:LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine 2LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine 3BCM-95 Demonstrates Superior Anti-Inflammatory Effects 2
(Date:4/18/2014)... School of Medicine researchers have been awarded two-year grants ... Nordisk announced this month. Of the 110 initial submissions ... Science Forum Program, only four projects were funded, three ... are Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; ... a professor of oncology, will use his $500,000 proof ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... has been effective for inoperable liver cancer. It is a year since ... a 25 ... rate in either reducing tumour size or the number of tumours. Till ... tumours, who cannot be treated by any other means. ,TheraSphere ...
... who suffer from dementia benefit from music therapy. The therapy ... The trials have found that the therapy is popular with ... at Imperial College London are planning to carry out a ... has long term benefits for dementia sufferers. If their results ...
... with low birth weight can significantly improve survival rates, ... diseases. The research involved 1,154 full-term but smaller than ... 5 1/2 pounds or less. Mothers fed them supplements ... the 20 who died had not been receiving zinc ...
... sole franchisee for US based Medicine Shoppe International, with operations ... from list of its target for operations in the country. ... to expand its franchisee operations from the present 19 outlets ... has decided to put on hold the commencing of operations ...
... a heavy breakfast and a steaming cup of tea may increase ... fried food each morning are at twice the risk of ... to reduce the incidence of cancer is to begin the day ... ,Cancer of the oesophagus - the food pipe connecting the stomach ...
... are more likely to get diagnosed with the progressive brain ... the case, although some have suggested that the disease may ... before it manifests itself elsewhere. ,Dr Robert Abbott, ... effectively identify people with early or suspected disease or people ...
Cached Medicine News:Health News:Cut down on fries 2